Literature DB >> 24806819

Polymorphisms of neonatal Fc receptor in cynomolgus and rhesus macaques.

Yasuhiro Uno1, Masahiro Utoh, Kazuhide Iwasaki.   

Abstract

Neonatal Fc receptor (FcRn), a heterodimer of MHC class I-like protein and β2-microglobulin, encoded by FCGRT and B2M, respectively, is important for recycling immunoglobulin G (IgG) antibodies by binding with the Fc region of IgG. Cynomolgus macaques are important animal species used in the evaluation of therapeutic antibodies, largely due to sequence similarities of target proteins to those of humans. Because the function of FcRn could be modified by mutations in FCGRT or B2M, 71 cynomolgus and 24 rhesus macaques were analyzed in the present study. A total of 21 variants were identified, of which 4 were non-synonymous in FCGRT. Fifteen variants were unique to cynomolgus macaques, of which 3, 2, and 5 were unique to cynomolgus macaques bred in China (MacfaCHN), Cambodia (MacfaCAM), and Indonesia (MacfaIDN), respectively. Five variants were shared by MacfaCHN and MacfaCAM, but not by MacfaIDN. In B2M, only 5 variants were found, including 2 non-synonymous variants. Tissue expression analysis showed that cynomolgus FCGRT and B2M were widely expressed in the 10 tissue types analyzed. None of the non-synonymous variants of FCGRT or B2M found changes in the amino acid residues known to be important for FcRn function, suggesting that substantial inter-animal variability of FcRn is not expected for the cynomolgus macaques analyzed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24806819     DOI: 10.2133/dmpk.dmpk-14-nt-033

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  5 in total

1.  Functional polymorphisms in rhesus macaque FCGRT and β2-m.

Authors:  Zhanna Shubin; Yutaka Tagaya; Bhawna Poonia
Journal:  Immunogenetics       Date:  2017-08-07       Impact factor: 2.846

Review 2.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

3.  FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric-coated capsules in cynomolgus macaques.

Authors:  Salman Muzammil; John R Mabus; Philip R Cooper; Randall J Brezski; Courtney B Bement; Rob Perkinson; Norman D Huebert; Suzanne Thompson; Dalia Levine; Connie Kliwinski; Dino Bradley; Pamela J Hornby
Journal:  Pharmacol Res Perspect       Date:  2016-04-25

4.  Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.

Authors:  Bryan Smith; Andrea Kiessling; Rocio Lledo-Garcia; Kate L Dixon; Louis Christodoulou; Matthew C Catley; Paul Atherfold; Lena E D'Hooghe; Helene Finney; Kevin Greenslade; Hanna Hailu; Lara Kevorkian; Daniel Lightwood; Christoph Meier; Rebecca Munro; Omar Qureshi; Kaushik Sarkar; Sophie P Shaw; Roohi Tewari; Alison Turner; Kerry Tyson; Shauna West; Stevan Shaw; Frank R Brennan
Journal:  MAbs       Date:  2018-09-12       Impact factor: 5.857

Review 5.  Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function.

Authors:  Andrew R Crowley; Margaret E Ackerman
Journal:  Front Immunol       Date:  2019-04-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.